NXTCNasdaqPharmaceutical PreparationsFiscal year ends December 31

NextCure, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026

$5.67−0.57 (-9.13%)

Close on Oct 19, 2026

Market cap: $30.11M
P/E (TTM): –
Dividend yield: 0.00%

NextCure, Inc. cash flow statement

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31
Depreciation & Amortization	2.20	2.90	3.70	4.10	4.30	3.40	2.69	1.68
Stock-Based Compensation	2.99	6.34	8.19	9.51	10	7.91	1.89	0.26
Change in Accounts Payable	-3.34	3.02	-1.94	2.33	-1.96	2.04	-0.62	1.34
Operating Cash Flow	-50	-41	-53	-54	-57	-45	-36	7.99
Capital Expenditures	–	-0.47	-0.82	-2.12	-2.36	-7.13	-3.37	-3.06
Purchase of Investments	-27	-48	-74	-35	-156	-137	-301	–
Sale & Maturity of Investments	52	104	114	105	195	188	–	–
Investing Cash Flow	26	55	39	68	37	44	-304	-3.06
Stock Issued	–	0.04	0.01	–	–	0.11	0.12	0.00
Debt Issued	–	–	–	–	–	–	4.54	–
Debt Repaid	–	–	–	–	-3.47	-1.53	–	-0.40
Financing Cash Flow	22	0.14	0.15	0.20	-3.27	-1.42	243	121
Net Change in Cash	-1.75	15	-14	14	-24	-2.85	-97	126
Free Cash Flow	–	-41	-54	-56	-60	-52	-39	4.93
Interest Paid	0.06	0.07	0.08	0.09	0.16	0.13	0.19	0.03

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: -111.2%

Financial strength

Current ratio: 3.47
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 238.0%

Valuation

P/E ratio: –
Price to sales: –
Price to book: 2.48
Dividend yield: 0.00%